| Summary: | Dyslipidemia (DLP) represents one of the most significant risk factors of atherosclerosis. Results of many clinical studies proved that effective treatment of dyslipidemia markedly decreases cardiovascular risk. Hypolipidemic treatment becomes one of the most effective treatment options (modalities) in prevention of CHD (coronary heart disease) and other cardiovascular diseases. Basic approach of the DLP treatment is nonpharmacologic therapy, e.g. change of life habits, stop of smoking, change of dietary habits, regular exercise, reduction of abnormal weight. In primary prevention settings the pharmacotherapy should commence after the failure of 3 to 6 months nonpharmacologic measures. In secondary prevention in patients with CHD it is recomended to start DLP treatment immediately, at the latest on release from the hospital. The care for the patient with hyperlipoproteinemia is comprehensive and should include rational control of diabetes, hypertension, obesity, adequate treatment of CHD and complications of atherosclerosis. The statins are the choice of medication in isolated hyperlipoproteinemia. If the target values are not reached by monotherapy, combination therapy by statin end ezetimib may be tried. The choice of lipid lowering drug should be decided on the major metabolic abnormality. When...
|
|---|
